" The quality of life is more important that life itself."
Alexis Carrel
Paramount
BioPharma
About Us
About Us
We are a clinical stage biotechnology company working on a new and better way to treat cancer.
Our patented technology focusses on extending patient survival with a strong emphasis on the quality of life during the treatment period.
Our Science
Our patented first-in-class synthetic molecules induce an immune response to target the tumour micro environment.
We can target multiple active pathways and address different indications of cancer.
Clinical data supports a low toxic profile and this makes us the preferred option for treatment as a monotherapy or combination
Our Pipeline
We have an approved Phase I/II clinical trial in a combination treatment for mutated colorectal cancer and a pipeline plan for clinical trials in multiple indications of solid tumours.
Unique Novel Approach
How are we different?
Target the tumour micro environment and not the tumour
Active stimulation of antibody response to target growth factors active in cancer cell proliferation
Lower toxicity offering a better quality of life during treatment
Huge Potential
We aim to produce medicines that are the preferred choice for use as a mono therapy and as combinations with existing cancer treatments
We augment existing treatments by delaying resistance without adding toxicity
We can target many different indications of solid tumour cancers
A lower toxic profile makes us the preferred choice for mono or combination treatment
Versatile Platform
Our platform technology can produce different molecules to address single or multiple pathways active in cancer proliferation
Our platform can create different molecules to target different cancers
Easy and replicable
manufacturing process
Can induce antibodies to target a single or multiple growth factors
Paramount
BioPharma
Address
Boston, MA, USA
Contact
johan@paramountbiopharma.com